Physician profile
Mohammad Ismail
NPI 1730105784
$5,508.88
in general payments reported to CMS, 2019-2025
20 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $2,271 · 2021: $125 · 2022: $463 · 2023: $889 · 2024: $800 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,932 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,931.54 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $2,240.21 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $606.52 | 2019-2023 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $407.40 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $363.94 | 2019-2023 | Jynarque |
| Aurinia Pharma U.S., INC. | $344.54 | 2022-2023 | Lupkynis |
| Sanofi-Aventis U.S. LLC | $296.19 | 2024 | |
| Akebia Therapeutics INC | $248.35 | 2019-2025 | Vafseo, Auryxia |
| Amgen INC. | $239.24 | 2019-2021 | |
| Vifor Pharma, INC. | $183.59 | 2019-2025 | Veltassa |
| Ardelyx, INC. | $155.99 | 2023-2024 | Xphozah 30 Mg, Ibsrela |
| Glaxosmithkline, LLC. | $134.52 | 2023-2024 | Jesduvroq, Benlysta |
| Travere Therapeutics, INC. | $94.59 | 2024 | |
| Fresenius USA Marketing, INC. | $91.10 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $57.53 | 2019-2021 | |
| Catalyst Pharmaceuticals, INC. | $20.05 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $13.27 | 2024 | Zio Xt Patch, Zio Monitor |
| Opko Pharmaceuticals, LLC | $11.85 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Ismail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.